SinoMab BioScience Limited
中國抗體製藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 3681)

VOLUNTARY ANNOUNCEMENT
FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF SM17 FOR ATOPIC DERMATITIS IN CHINA

Reference is made to the announcements of SinoMab BioScience Limited (中國抗體製藥有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") dated 16 February 2022, 14 March 2022, 15 June 2022, 22 May 2023, 12 June 2023, 14 August 2023, 11 September 2023, 27 November 2023, 11 June 2024, 7 April 2025, 14 October 2025, 11 December 2025, 24 February 2026 and 25 March 2026 in relation to the latest research and development progress of one of the Group's key products, SM17.

The board of directors (the "**Board**") of the Company is pleased to announce that, on 31 March 2026, the first patient has been successfully dosed in a Phase 2 clinical trial of SM17 for the treatment of Atopic Dermatitis ("**AD**") in China.

The Phase 2 study is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of SM17 subcutaneous formulation in approximate 210 patients with moderate-to-severe AD. Patients will be randomized into 5 groups (1:1:1:1:1) to receive subcutaneous treatment of different doses of SM17 or placebo. The primary endpoint is percentage change from baseline (CFB) in Eczema Area and Severity Index (EASI) at Week 16, and secondary endpoints (including other efficacy endpoints, such as portion of subjects reaching EASI50, EASI75, EASI90, IGA0/1, safety endpoints defined as incidence of TEAE, pharmacokinetics (PK) profile, pharmacodynamics (PD) profiles, as well as immunogenicity) will be assessed at week 16 and other time points across the study until week 24.

SM17 is a novel, first-in-class (FIC) humanized IgG4-k monoclonal antibody designed to modulate Type 2 inflammatory responses by targeting the receptor of interleukin-25 (IL-25), an alarmin molecule central to Type 2 immunity. By binding to the IL-25 receptor (IL17RB) on Type 2 innate lymphoid cells (ILC2s) and Th2 cells, SM17 inhibits IL-25-mediated signaling and suppresses downstream inflammatory cytokines including interleukin-4, interleukin-5 and interleukin-13.

IL-25 is a critical cytokine classified as ''alarmin'', which has shown to be implicated in the pathogenesis of multiple inflammation and immunology diseases, such as AD, asthma and inflammatory bowel disease (IBD). Despite advances in targeted therapies, these chronic inflammatory and immune-mediated diseases remain associated with substantial disease burden, including persistent symptoms, progressive tissue damage, and significant impairment in quality of life. Current treatments, while effective in many patients, are often limited by safety concerns, suboptimal adherence, and a subset of patients who fail to achieve durable remission. These unmet needs underscore the continued demand for novel therapeutic options that offer improved convenience, favorable safety profiles, and differentiated efficacy.

On April 7, 2025, the Company announced positive topline results of SM17 from Phase 1b study in patients with moderate-to-severe AD in China. The 12-week topline data after unblinding showed that in the high dose group, 91.7% of patients achieved pruritus relief (NRS-4), 75% achieved skin healing (EASI 75), and 41.7% achieved clear or almost clear signs of AD (IGA 0/1). These results demonstrated the competitive advantages of SM17 as the potential first AD biologic with dual efficacy in pruritus relief and skin healing. On March 27, 2026, the Company announced that the Phase 1 bridging study for the route of administration conversion of SM17 achieved favorable topline results: healthy participants dosed with subcutaneous formulation achieved favorable tolerability and safety profile and the PK profiles for the subcutaneous formulation support a smooth route-of administration conversion.

The Company believes that therapies targeting upstream of the Th2 inflammatory cytokine pathway, such as IL-25 receptor, will have broad effects on skin inflammation, implicating a great potential for SM17 as a differentiating, safer and more effective products for the treatment of AD.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 1 April 2026

As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Ms. Xiaosu WANG and Dr. Jianmin ZHANG, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE, Ms. Chi Sau Giselle LEE and Mr. Nan SHEN.